Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics: Is Elevidys A Bust?
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reiterates a $500M annual revenue floor and expects normalization in ambulatory demand to support growth. SRPT fundamentals are robust, with nearly $1B in cash, no near-term debt, and a stable PMO franchise generating almost $1B in 2025 revenue.
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
Sarepta Therapeutics is upgraded to a buy following HHS's addition of Duchenne muscular dystrophy to the newborn screening panel. Earlier DMD detection aligns perfectly with SRPT's preventative therapies, expanding the eligible patient pool and improving payer reimbursement prospects. The company recently refinanced a significant portion of its debt, extending maturities and enhancing financial flexibility despite a higher interest rate.
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients with Duchenne muscular dystrophy.
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Sarepta Therapeutics Stock Tumbles After Trial Data
Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript
Sarepta Therapeutics, Inc. ( SRPT ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research & Development and Technical Operations Patrick Moss - Executive VP & Chief Commercial Officer Ryan Wong - Executive VP & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Huidong Wang - Barclays Bank PLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Kevin Meli - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Gil Blum - Needham & Company, LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Michael Ulz - Morgan Stanley, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Ritu Baral - TD Cowen, Research Division David Hoang - Deutsche Bank AG, Research Division Biren Amin - Piper Sandler & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Samantha Corwin - William Blair & Company L.L.C.
Sarepta slumps as gene therapy setback adds to drug pipeline woes
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.
